Experimental studies reveal that MNPs induce oxidative stress, inflammation, mitochondrial dysfunction and cell death in cardiac cells, potentially contributing to myocardial damage, fibrosis and maladaptive remodelling
In fact, MitoQ has been used in a range of in vivo studies, in rats and mice, and in two phase II human trials demonstrating that it can be safely delivered to patients with promising results, lending further support that mitochondria-targeted antioxidants may be applicable to a wide range of human pathologies that involve mitochondrial oxidative damage (Smith and Murphy, 2010)
& Koike, K
Here is a fact most skincare brands would rather you didn't know: by the time you notice your skin has changed in midlife, the structural decline is already well underway
Can triple agonism outperform incretin therapy
Studies have demonstrated not only visceral fat loss, increased skeletal muscle, and improved body composition,9 17 18 but also elevated secretions of growth hormone and IGF-1.19 But when the body experiences changes in one area of function, it can have a cascading effect on other areas as well
